Fig. 4
From: Comparative in vivo characterization of newly discovered myotropic adeno-associated vectors
Comparison of transduction levels in different organs between AAV9 and myotropic AAVs in mice 4 weeks after retro-orbital injection at 1 day post-natal. WT CD1 or C57BL/6 mice were systemically injected at 1 d.p.n. with 4.1E + 12 vg/kg of AAV9-, AAVMYO-, MyoAAV2A-, or MyoAAV4A-CMV-luc-IRES-eGFP and analyzed 4 weeks later. (A) Quantification of eGFP mRNA fold change expression of AAVMYO-, MyoAAV2A-, MyoAAV4A- and AAV9-CMV-luc-IRES-eGFP in WT CD1 and C57BL/6 mice in different organs. Data are presented as mean values +/- SEM (n = 5–6). One-way ANOVA with Tukey correction. *p < 0.05, **p < 0.01, ****p < 0.0001 versus AAV9 ; ##p < 0.01, ####p < 0.0001 versus AAVMYO ; §p < 0.05, §§p < 0.01, §§§p < 0.001, §§§§p < 0.0001 versus MyoAAV4A. (B) Quantification of luciferase activity of AAVMYO-, MyoAAV2A-, MyoAAV4A- and AAV9-CMV-luc-IRES-eGFP in WT CD1 and C57BL/6 mice in different organs. Data are presented as mean values +/- SEM (n = 5–6). One-way ANOVA with Tukey correction. *p < 0.05, **p < 0.01, ****p < 0.0001 versus AAV9 ; $$p < 0.01, $$$p < 0.001 versus MyoAAV2A ; §§p < 0.01, §§§p < 0.001, §§§§p < 0.0001 versus MyoAAV4A